The study investigates the anticancer potential of Annona muricata by identifying and analyzing its bioactive compounds through network pharmacology and molecular docking studies. Key compounds such as (+)-Anomurine, Annonaine, Quercetin 3-O-glucoside, and Genistein were identified and linked to critical molecular targets like PAR2, STAT3, AKT1, and TP53, which are pivotal in the progression of pancreatic cancer. Pathway enrichment analysis provided information of the association of these targets in vital biochemical progression, together with apoptosis, cell cycle regulation, and immune responses. Further analysis revealed 17 intersecting genes, including PAR2, BRCA2, KRAS, and TP53, emphasizing their roles in cancer-related pathways. Molecular docking examination demonstrated tough binding attraction of compounds like Blumenol C, Annopentocin A, and Genistein with target proteins, suggesting significant therapeutic potential. The findings indicate that Annona muricata could serve as a promising therapeutic agent against cancer, particularly pancreatic cancer, though additional investigational confirmation and clinical studies are necessary to verify its effectiveness and safety.
Keywords: Annona muricata, bioactive compounds, network pharmacology, molecular docking, pancreatic cancer, PAR2, STAT3, TP53, apoptosis, pathway enrichment, cancer therapy, molecular targets, DNA repair, genomic stability
How to cite this article: Bakhshi A, Shirole R, Deshpande A, Kothawade K, More V, Gurav Y, Molecular Mechanisms of Annona Muricata Against Pancreatic Cancer: A Network Pharmacology and Molecular Docking Study. Int J Drug Deliv Technol. 2025;15(4): 1720-1730, DOI: 10.25258/ijddt.15.4.23